Genocea Biosciences Inc. Stock
Your prediction
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -1.610% | -0.093% | 14.255% | -72.306% | -61.293% | -71.444% | -95.712% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
